In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback has been integrated and CADTH has now launched a pilot initiative to increase opportunities for clinicians who register with pCODR to provide input and feedback on a submission or resubmission.
This pilot initiative will be in effect for new pending pCODR submissions announced in February 2016 and onward.
It is strongly encouraged that clinicians register with the pCODR program well in advance to ensure eligibility to provide input and feedback on a future submission or resubmission and to receive notification of upcoming submissions. For more information about the registration process, please click on this link. The requirements for eligible clinicians are set out in the pCODR Procedures and pCODR Submission Guidelines. A FAQ page has also been created with more information for clinicians.
CADTH intends to evaluate this pilot initiative after 25 cancer drug submissions with clinical input have been received, or sooner, and will consult with stakeholders on any significant changes to the pCODR process.
For more information or questions regarding CADTH’s new pilot initiative for clinicians, please contact email@example.com